# 68Ga-NOTA-T4

Source: https://onco.cc/drugs/ga68-nota-t4/  
OnCo record `ga68-nota-t4` (Imaging agent). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An experimental PET scan from Shanghai that shows TROP2 in breast cancer, and showed that the amount of TROP2 changes with treatment.

## Summary

[68Ga]Ga-NOTA-T4 was studied at Huashan Hospital, Fudan University, in 42 patients with HER2-negative breast cancer imaged between September 2023 and March 2025 (Liu et al., European Journal of Nuclear Medicine and Molecular Imaging 2026), 27 of whom also had FDG PET. It identified patients and metastatic lesions about as well as FDG. Uptake differed with prior treatment: in luminal B disease, treated patients had higher uptake than untreated ones (maximum standardised uptake value 5.20 against 3.36, p = 0.008), while in triple-negative disease treated patients had lower uptake (3.02 against 7.63, p = 0.008). That is direct imaging evidence that TROP2 expression is not fixed and can move with therapy. A separate registered study at RenJi Hospital, NCT06851663, lists [68Ga]Ga-NOTA-T4 among its tracers.

## Fields

- Kind: Imaging agent
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: [68Ga]Ga-NOTA-T4; Gallium-68 NOTA-T4
- Tags: diagnostic; frontier
- Modality: Investigational PET imaging agent (TROP2-targeting tracer, gallium-68)
- Mechanism: A TROP2-targeting tracer labelled with gallium-68, imaged by PET to show TROP2 expression across all lesions.

## Notes

- A retrospective single-centre series; the authors describe the tracer as promising and its use for choosing treatment as untested.

## Sources

- Liu et al., [68Ga]Ga-NOTA-T4 PET/CT in HER2-negative breast cancer (Eur J Nucl Med Mol Imaging 2026): https://doi.org/10.1007/s00259-026-07796-4
- ClinicalTrials.gov NCT06851663: https://clinicaltrials.gov/study/NCT06851663

## Connected records

- drugs: [68Ga-MY6349](https://onco.cc/drugs/ga68-my6349/)
- ideas: [TROP2 PET to choose and sequence TROP2 ADCs](https://onco.cc/ideas/idea-trop2-pet-selection/)
- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [TROP2 PET](https://onco.cc/technologies/trop2-pet/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [Trop2-targeted immunoPET Imaging of Solid Tumors](https://onco.cc/trials/nct06851663/)
- key papers: [[68Ga]Ga-NOTA-T4 PET/CT imaging of TROP2 expression in patients with HER2-negative breast cancer](https://onco.cc/key-papers/paper-liu-ga68-nota-t4-breast-eur-j-nucl-med-2026/)

---
JSON: https://onco.cc/api/v1/entities/ga68-nota-t4.json